GLA
PCRX icon

Great Lakes Advisors’s Pacira BioSciences PCRX Stock Holding History

Great Lakes Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-65,581
Closed -$1.48M – 864
2026
Q1 		$1.48M Sell
65,581
-4,702
-7% -$104K 0.01% 468
2025
Q4 		$1.82M Sell
70,283
-35,460
-34% -$843K 0.01% 436
2025
Q3 		$2.72M Sell
105,743
-111,318
-51% -$2.73M 0.02% 379
2025
Q2 		$5.19M Sell
217,061
-18,100
-8% -$456K 0.04% 279
2025
Q1 		$5.84M Sell
235,161
-1,391
-0.6% -$33.3K 0.05% 256
2024
Q4 		$4.46M Sell
236,552
-233,540
-50% -$4.1M 0.04% 337
2024
Q3 		$7.07M Buy
+470,092
New +$8.04M 0.06% 253
2022
Q3 		– Sell
-153,238
Closed -$8.93M – 697
2022
Q2 		$8.93M Sell
153,238
-6,078
-4% -$398K 0.18% 149
2022
Q1 		$12.2M Sell
159,316
-37,564
-19% -$2.5M 0.2% 139
2021
Q4 		$11.8M Sell
196,880
-4,108
-2% -$227K 0.18% 162
2021
Q3 		$11.3M Sell
200,988
-7,166
-3% -$413K 0.18% 169
2021
Q2 		$12.6M Sell
208,154
-7,688
-4% -$487K 0.19% 163
2021
Q1 		$15.1M Buy
215,842
+16,258
+8% +$1.16M 0.24% 137
2020
Q4 		$11.9M Sell
199,584
-8,760
-4% -$513K 0.22% 133
2020
Q3 		$12.5M Buy
208,344
+31,591
+18% +$1.84M 0.27% 122
2020
Q2 		$9.27M Buy
176,753
+12,705
+8% +$531K 0.23% 123
2020
Q1 		$5.5M Sell
164,048
-215
-0.1% -$8.93K 0.16% 156
2019
Q4 		$7.44M Buy
+164,263
New +$6.98M 0.16% 164
2017
Q4 		– Sell
-122,083
Closed -$4.58M – 601
2017
Q3 		$4.58M Buy
122,083
+10,327
+9% +$416K 0.11% 164
2017
Q2 		$5.33M Sell
111,756
-1,705
-2% -$79.1K 0.13% 149
2017
Q1 		$5.17M Buy
113,461
+48,830
+76% +$2.11M 0.13% 143
2016
Q4 		$2.09M Sell
64,631
-656
-1% -$21.9K 0.05% 263
2016
Q3 		$2.23M Buy
+65,287
New +$2.56M 0.06% 252

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Great Lakes Advisors's PCRX Position: Q2 2026 in Review

Great Lakes Advisors sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 65,581 shares — an estimated $1.48M sold.

Great Lakes Advisors first reported a position in PCRX in Q3 2016 and held it in 23 quarters. The position peaked at $15.1M in Q1 2021. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Great Lakes Advisors reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
  • Great Lakes Advisors sold 65,581 Pacira BioSciences shares in Q2 2026, an estimated $1.48M.
  • Great Lakes Advisors first reported a position in Pacira BioSciences in Q3 2016 and held it in 23 quarters.
  • Great Lakes Advisors's Pacira BioSciences position peaked at $15.1M in Q1 2021.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.